920036-28-8

Basic information

• Product Name: 1H-PYRAZOLO[3,4-B]PYRIDINE,6-FLUORO-3-METHYL-
• Synonyms: 1H-PYRAZOLO[3,4-B]PYRIDINE,6-FLUORO-3-METHYL-;6-Fluoro-3-Methyl-1H-pyrazolo[3,4-b]pyridine
• CAS NO: 920036-28-8
• Molecular Formula: C7H6FN3
• Molecular Weight: 151.14
• Mol File: 920036-28-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1H-PYRAZOLO[3,4-B]PYRIDINE,6-FLUORO-3-METHYL-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-PYRAZOLO[3,4-B]PYRIDINE,6-FLUORO-3-METHYL-(920036-28-8)
• EPA Substance Registry System: 1H-PYRAZOLO[3,4-B]PYRIDINE,6-FLUORO-3-METHYL-(920036-28-8)

Safety Data

• Hazardous Substances Data: 920036-28-8(Hazardous Substances Data)

Usage

General Description

1H-Pyrazolo[3,4-b]pyridine,6-fluoro-3-methyl- is a chemical compound with the molecular formula C8H6FN3. It is a heterocyclic compound with a pyrazole ring fused to a pyridine ring, and a fluorine atom and a methyl group attached to the pyrazole ring. 1H-PYRAZOLO[3,4-B]PYRIDINE,6-FLUORO-3-METHYL- has potential applications in the pharmaceutical industry, particularly in the development of new drugs. It may also have utility as a research tool in the study of biological processes and interactions. Additionally, its unique structure and properties may make it useful in the synthesis of other organic compounds.

Upstream product

• 920036-27-7 1-(2,6-difluoropyridin-3-yl)ethanone 
• 171178-50-0 2,6-difluoronicotinic acid 
• 937399-53-6 2,6-difluoro-N-methoxy-N-methyl-pyridine-3-carboxamide 

Relevant articles and documents

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2- chlorophenoxy}-5-chlorobenzonitrile (MK-4965): A potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been shown to be a key component of highly active antiretroviral therapy (HAART). The use of NNRTIs has become part of standard combination antiviral therapies producing clinical outcomes with